“I realized each Center of Excellence across the country was doing something different,” said Angela P. Russell, PhD, NP, program administrator and clinical coordinator for the University of Miami (UM) Parkinson's Disease & Movement Disorders Center, a Parkinson’s Foundation Center of Excellence.
Earlier this month, members of the Parkinson’s Foundation team joined thousands of movement disorder specialists in Vancouver, Canada.
They were on site for the International Congress of Parkinson’s Disease and Movement Disorders, which brings together neurologists with expertise in Parkinson’s and similar diseases to share the latest in advancements in research and care.
Deep brain stimulation (DBS) is a therapy that has been administered to over 100,000 patients worldwide. The majority of people receiving deep brain stimulation live with a diagnosis of Parkinson’s disease (PD). The technique has been helpful for improving tremor, on-off fluctuations, dyskinesia, and off time. One of the main limitations of deep brain stimulation has been that it requires brain surgery and carries an associated risk of hemorrhage, stroke, infection, and hardware failure.
Should we consider subcutaneous apomorphine infusions for Parkinson’s disease patients who do not want deep brain stimulation or a dopamine pump? There is a growing interest among people with Parkinson’s disease (PD) and families for a “nonsurgical” alternative to deep brain stimulation (DBS) surgery or to Duopa pump therapy. The idea of brain surgery or a feeding tube have been cited as being undesirable for large numbers of PD patients.
Part of Steven Goldenthal’s job is to get people connected. He wants to know how they feel, gets to know their medical history, what medications they take and if they are happy with their Parkinson’s disease (PD) care.
Something resonated with me on my recent visit to the Beth Israel Deaconess Medical Center, a Parkinson’s Foundation Center of Excellence (COE). As I listened to the Parkinson’s patients and caregivers panel, I was impressed to learn that everyone unanimously agreed on the vital importance of team care. From the movement disorder specialist to the nurse, everyone kept referring to “our” care plan. It was working.
Considerable evidence has been mounting in support of a relationship between the gastrointestinal (GI) system and Parkinson’s disease (PD). Many pathologists and neurologists even believe that Parkinson’s may start in the gut, but this view remains speculative. Many GI symptoms, such as constipation, occur as prominent and disabling PD symptoms. In the July 2013 What’s Hot in PD? column, I addressed H.
Who has the highest risk of injury among people with Parkinson’s disease (PD)? Is there a connection between medication combinations and falling less? Are prescription antipsychotics safe? Earlier this year, NPF presented four posters at the World Parkinson Congress (WPC) that answered these questions and more.
Ted Dawson, PhD, and colleagues at the Johns Hopkins University, a National Parkinson Foundation Center of Excellence, have uncovered a potential new approach to treat Parkinson’s disease (PD). Researchers in Dawson’s laboratory focused on a protein called lymphocyte-activation gene 3, known as LAG3. This protein has been shown to be important in cell to cell transfers of α-synuclein (Lewy bodies), which is a protein found in the brain of a person with PD.
While reviewing data from the National Parkinson Foundation’s (NPF) Parkinson’s Outcomes Project a year ago, I noticed a participant whose quality of life went from pretty good to terrible, then back to pretty good. I wondered, “what happened here?” The answer: psychosis.